Showing results (31-40 of 70) with videos related to
Sort By:
Pageof 7
Journal of Neuroscience Methods|December 14, 2004
In vivo autofluorescence spectrofluorometry of central serotoninFrancesco Crespi, Anna C Croce, Sabrina Fiorani, et al.Journal of Neuroscience Methods|August 25, 2004
High-performance liquid chromatography/tandem mass spectrometric assay for the simultaneous measurement of dopamine, norepinephrine, 5-hydroxytryptamine and cocaine in biological samplesMark E P Hows, Laurent Lacroix, Christian Heidbreder, et al.Clinical Pharmacokinetics|July 13, 2014
A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependenceAzmi F Nasser, Christian Heidbreder, Roberto Gomeni, et al.Clinical Pharmacokinetics|January 28, 2014
Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatmentCeline M Laffont, Roberto Gomeni, Bo Zheng, et al.Journal of Clinical Pharmacology|July 22, 2014
Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidoneCeline M Laffont, Roberto Gomeni, Bo Zheng, et al.Frontiers in Pharmacology|December 5, 2022
Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorderCeline M Laffont, Eliford Ngaimisi, Mathangi Gopalakrishnan, et al.The Journal of Pharmacy and Pharmacology|October 27, 2016
Improving the oral bioavailability of buprenorphine: an in-vivo proof of conceptAnand Joshi, Matthew Halquist, Zacharoula Konsoula, et al.Synapse (New York, N.Y.)|August 10, 2004
Selective dopamine D(3) receptor antagonist SB-277011-A potentiates phMRI response to acute amphetamine challenge in the rat brainAdam Schwarz, Alessandro Gozzi, Torsten Reese, et al.British Journal of Clinical Pharmacology|January 31, 2017
Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidoneVijay Ivaturi, Mathangi Gopalakrishnan, Jogarao V S Gobburu, et al.Journal of Clinical Psychopharmacology|July 26, 2019
Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia: Results From the Phase 3 ProgramAnne Andorn, Jay Graham, John Csernansky, et al.Pageof 7